Abstracts Archive - Page 1080 of 2607 - ACR Meeting Abstracts

Abstract Number: 2099 • 2019 ACR/ARP Annual Meeting
Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong
Yan Ki Tang¹, Ho So ², Weng Nga Virginia Lao ², Hin Ting Pang ², Tak Lung Victor Wong ², Tsz Ho Luk ² and Man Lung Ronald Yip ³, ¹Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ²Department of Medicine & geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ³Tung Wah Group of Hospitals Integrated Diagnostic and Medical Centre, Hong Kong, Hong Kong
Background/Purpose: Screening for latent tuberculosis infection (LTBI) before the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) is recommended internationally especially in…
Abstract Number: 2100 • 2019 ACR/ARP Annual Meeting
Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients
Robyn Moran¹, Jenna Beatty ¹, Jon Ternus ¹ and Megan Krause ², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, KANSAS CITY, KS
Background/Purpose: Rituximab is used to treat a variety of rheumatic diseases. In 2015, the American Gastroenterological Association (AGA) categorized rituximab as high-risk in terms of…
Abstract Number: 2101 • 2019 ACR/ARP Annual Meeting
Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Matthew Malus¹, Ly-Elaine Pham ¹, Hrishikesh Samant ¹ and Mamatha Katikaneni ², ¹Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, ²LSUHSC- Shreveport, Shreveport, LA
Background/Purpose: Chronic Hepatitis C virus infection (HCV) has been shown to be associated with connective tissue diseases (CTD). It has been hypothesized that HCV can…
Abstract Number: 2102 • 2019 ACR/ARP Annual Meeting
First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients
Francisco Conesa-Buendia¹, Patricia Atencio ¹, Alfonso Cabello ², Patricia Llamas-Granda ³, Ignacio Mahillo-Fernández ⁴, Raquel Largo ⁵, Gabriel Herrero-Beaumont ⁵, Miguel Gorgolas ¹ and Aranzazu Mediero ¹, ¹IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, ²IIS FUNDACION JIMENEZ DIAZ, Madrid, Spain, ³IIS-FUNDACION JIMENEX DIAZ, Madrid, Spain, ⁴IIS- FUNDACION JIMENEZ DIAZ, Madrid, Spain, ⁵IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: For almost two decades, bone alterations have been observed in the course of HIV infection, characterized by a marked decrease in bone mineral density…
Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting
Anti-TNF Therapy in Patients with HIV Infection
Joanna Marco¹ and Alison Bays ², ¹University of Washington, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, WA
Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…
Abstract Number: 2104 • 2019 ACR/ARP Annual Meeting
Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Courtney McCray¹, Gloria Salazar ², Ryan Valicek ¹, Binh Nguyen ³, Benjamin Naovarat ⁴, Francis Williams ² and John Reveille ², ¹University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, ³University of Texas McGoven Medical School, Houston, ⁴University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: A large spectrum of vasculitides affecting small, medium, and large vessels have been reported in HIV-infected individuals. Although vasculitis is a rare manifestation of…
Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Kengo Akashi¹, Sadao Jinno ², Akira Onishi ¹, Mai Yamashita ³, Yoko Nose ⁴, Takaichi Okano ¹, Yo Ueda ¹, Sho Sendo ¹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ⁴Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
Abstract Number: 2106 • 2019 ACR/ARP Annual Meeting
Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Sara Sabbagh¹, Jessica Neely ², Jamie Lai ³, Anjali Sura ⁴, Kelly Rouster-Stevens ⁵, Svetlana Lvovich ⁶, Tara McGrath ⁷, Lori Tucker ⁸, Heinrike Schmeling ⁹, Jordan Roberts ¹⁰, Lisa G. Rider ¹¹ and Susan Kim ², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Pediatrics, University of Colorado School of Medicine, Division of Pediatric Rheumatology, Children’s Hospital Colorado, Aurora, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Section of Rheumatology, Department of Pediatrics, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, PA, ⁷Division of Rheumatology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada, ⁸British Columbia Children’s Hospital, Vancouver, Canada, ⁹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Boston Children’s Hospital, Harvard Medical School, Boston, MD, ¹¹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Approximately 6% of adults with idiopathic inflammatory myopathy (IIM) develop Pneumocystis jirovecii pneumonia (PJP), and PJP confers higher mortality in IIM patients compared to…
Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting
Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Eishi Uechi¹ and Kiyohide Fushimi ², ¹Tomishiro Central Hospital, Tomigusuku city, Okinawa, Japan, ²Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…
Abstract Number: 2108 • 2019 ACR/ARP Annual Meeting
Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients
Yoichi Nakayama¹, Eisaku Tanaka ², Masakuni Ueyama ³, Satoru Terada ², Takashi Inao ², Yusuke Kaji ², Takehiro Yasuda ², Seishu Hashimoto ², Takashi Hajiro ² and Yoshio Taguchi ², ¹Tenri Hospital, Department of General Internal Medicine, Tenri, Nara, Japan, ²Tenri Hospital, Department of Respiratory Medicine, Tenri, Nara, Japan, ³Tenri Hospital, Department of Respiratory Medicine, Tenri, Japan
Background/Purpose: Rheumatoid arthritis (RA) patients have increased susceptibility to infection by pulmonary nontuberculous mycobacterial disease (pNTM) compared with the healthy population. The reason for this…
Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Jaime Coral-Enriquez ¹, Mauricio Restrepo ², Gloria Vasquez ³, Carlos H Muñoz-Vahos ⁴, Daniel Jaramillo ⁵, Adriana Vanegas-García ⁴, Ruth Eraso ⁶, Johanna Hernández ⁷, Fabian Jaimes ⁸ and Luis Gonzalez², ¹Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ²Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, ³University of Antioquia, Medellin, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, ⁶Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, ⁷Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, ⁸Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
Abstract Number: 2110 • 2019 ACR/ARP Annual Meeting
Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico
Guillermo Guaracha-Basañez¹, Carla M. Román-Montes ², María F. González-Lara ² and Alfredo Ponce-de-León ², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Fungal infections are an important cause of morbidity and mortality in patients with rheumatic diseases. Invasive aspergillosis (IA) is a fungal infection potentially fatal,…
Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Travis Maestas ¹, Jaclyn Leong ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
Abstract Number: 2112 • 2019 ACR/ARP Annual Meeting
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Alazne Ruiz ¹, Juan Ramón De Dios ², Belen Alvarez ¹, Margarida Vasques Rocha ², Claudia Stoye ², Susana Gil ¹, Orlando Pompei Fernández ² and Jaime Calvo-Alen³, ¹Hospital Universitario Araba, Vitoria, Pais Vasco, Spain, ²Araba University Hospital, Vitoria, Pais Vasco, Spain, ³Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: To study frequency and associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods: All the medical records of the…
Abstract Number: 2113 • 2019 ACR/ARP Annual Meeting
Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever
Aline Razolin ¹, Claudia Marques ¹, Laurindo Rocha Jr², Hugo Lima ³, Lays Martins ¹, Anderson Almeida ¹, Priscila Oliveira ¹, Angela Duarte ¹, Moacyr Rego ¹, Maira Pitta ⁴ and Ieda Laurindo ⁵, ¹Universidade Federal de Pernambuco, Recife, Brazil, ²Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ³Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Pernambuco, Brazil, ⁴Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil, ⁵BIOBADABRASIL comittee, São Paulo
Background/Purpose: Background/purpose. The first chikungunya fever outbreak in Brazil had its peak in the first half of 2016 and many patients with rheumatologic disease using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].